AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 11841454 — intervention group
Group type: EXPERIMENTAL
Intervention: 8 microg/kg/d rhG-CSF
Number of subjects: 50
Study 11841454 — intervention group
Group type: EXPERIMENTAL
Intervention: 16 microg/kg/d rhG-CSF
Number of subjects: 50
Study 10191336 — intervention group
Group type: COMPARATOR
Intervention: Grip force adjustments in older adults (60 years and older) when friction of gripped surfaces was varied randomly.
Number of subjects: 0
Study 10191336 — intervention group
Group type: COMPARATOR
Intervention: Grip force adjustments in older adults (60 years and older) on slippery surfaces during friction variation experiments.
Number of subjects: 0
Study 10191336 — intervention group
Group type: COMPARATOR
Intervention: Grip force adjustments in older adults (60 years and older) compared to young subjects.
Number of subjects: 0
Study 10191336 — intervention group
Group type: COMPARATOR
Intervention: Anticipatory control of fingertip forces using memory of object weight in older adults.
Number of subjects: 0
Study 10191336 — intervention group
Group type: COMPARATOR
Intervention: Fingertip force modulation in old and young adults.
Number of subjects: 0
Study 7758326 — intervention group
Group type: EXPERIMENTAL
Intervention: 5% sodium lauryl sulphate at 4 degrees C
Number of subjects: 10
Study 7758326 — intervention group
Group type: EXPERIMENTAL
Intervention: 5% sodium lauryl sulphate at 20 degrees C
Number of subjects: 10
Study 7758326 — intervention group
Group type: EXPERIMENTAL
Intervention: 5% sodium lauryl sulphate at 40 degrees C
Number of subjects: 10
Study 7758326 — intervention group
Group type: COMPARATOR
Intervention: Untreated control site
Number of subjects: 10
Study 2189276 — intervention group
Group type: EXPERIMENTAL
Intervention: Ankerplast Spray
Number of subjects: 597
Study 2189276 — intervention group
Group type: COMPARATOR
Intervention: Control group (no Ankerplast Spray)
Number of subjects: 597
Study 582395 — intervention group
Group type: EXPERIMENTAL
Intervention: Ephedrine
Number of subjects: 60
Study 582395 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study 582395 — intervention group
Group type: EXPERIMENTAL
Intervention: Anger-provoking situation
Number of subjects: 60
Study 582395 — intervention group
Group type: COMPARATOR
Intervention: Neutral control situation
Number of subjects: 60
Study 31969796 — intervention group
Group type: EXPERIMENTAL
Intervention: CABG
Number of subjects: 155
Study 31969796 — intervention group
Group type: EXPERIMENTAL
Intervention: HCR
Number of subjects: 155
Study 31969796 — intervention group
Group type: EXPERIMENTAL
Intervention: MV-PCI
Number of subjects: 155
Study 30549366 — intervention group
Group type: EXPERIMENTAL
Intervention: Transtheoretical model (TTM)-based intervention
Number of subjects: 92
Study 30549366 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 92
Study 28973414 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.2% polidocanol diluted in 70% hypertonic glucose (HG)
Number of subjects: 93
Study 28973414 — intervention group
Group type: COMPARATOR
Intervention: 75% hypertonic glucose (HG) alone
Number of subjects: 93
Study 28973414 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 93
Study 26254820 — intervention group
Group type: EXPERIMENTAL
Intervention: Microvascular couplers used for anastomosis
Number of subjects: 64
Study 26254820 — intervention group
Group type: EXPERIMENTAL
Intervention: Microvascular couplers used for venous anastomosis
Number of subjects: 64
Study 24078483 — intervention group
Group type: EXPERIMENTAL
Intervention: Active group received LLLT using a 'TOPHAT655' unit with 21 lasers (5 mW, 655 ± 5 nm) and 30 LEDs (655 ± 20 nm), treated at home every other day for 16 weeks (60 treatments).
Number of subjects: 44
Study 24078483 — intervention group
Group type: COMPARATOR
Intervention: Placebo group received a unit with incandescent red lights, treated at home every other day for 16 weeks (60 treatments).
Number of subjects: 44
Study 20683712 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin D supplementation (800 IU/day)
Number of subjects: 232
Study 20683712 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin D supplementation (100,000 IU/3 months)
Number of subjects: 232
Study 20683712 — intervention group
Group type: COMPARATOR
Intervention: Advised sunlight exposure
Number of subjects: 232
Study 20683712 — intervention group
Group type: EXPERIMENTAL
Intervention: All groups (including sunlight exposure)
Number of subjects: 232
Study 20683712 — intervention group
Group type: EXPERIMENTAL
Intervention: Physical performance and functional limitations
Number of subjects: 232
Study 19664320 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive-behavioural group therapy (CBGT)
Number of subjects: 27
Study 17684199 — intervention group
Group type: EXPERIMENTAL
Intervention: Methylphenidate (MPH) 0.5 mg/kg
Number of subjects: 14
Study 17684199 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 14
Study 15305399 — intervention group
Group type: EXPERIMENTAL
Intervention: Concomitant administration of epirubicin (90 mg/m2) and paclitaxel (200 mg/m2) for 8 cycles
Number of subjects: 202
Study 15305399 — intervention group
Group type: COMPARATOR
Intervention: Sequential administration of epirubicin (120 mg/m2 for 4 cycles) followed by paclitaxel (250 mg/m2 over 3 hours for 4 cycles)
Number of subjects: 202
Study 11453871 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin E-modified membrane (E)
Number of subjects: 44
Study 11453871 — intervention group
Group type: COMPARATOR
Intervention: Nonmodified cellulose membrane (O)
Number of subjects: 44
Study 11453871 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin E-modified membrane (E) with Vitamin C infusion (C)
Number of subjects: 44
Study 11453871 — intervention group
Group type: COMPARATOR
Intervention: Nonmodified cellulose membrane (O) with Vitamin C infusion (C)
Number of subjects: 44
Study 11453871 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin E-modified membrane (E) in long-term study with Vitamin C (C)
Number of subjects: 44
Study 11453871 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin E-modified membrane (E) in long-term study without Vitamin C (C)
Number of subjects: 44
Study 11453871 — intervention group
Group type: COMPARATOR
Intervention: Switch to Nonmodified cellulose membrane (O)
Number of subjects: 44
Study 9749148 — intervention group
Group type: EXPERIMENTAL
Intervention: MAPA‐PC software for comparing ABPM
Number of subjects: 79
Study 9749148 — intervention group
Group type: EXPERIMENTAL
Intervention: MAPA‐PC software
Number of subjects: 79
Study 7804393 — intervention group
Group type: EXPERIMENTAL
Intervention: Acetazolamide
Number of subjects: 16
Study 2454128 — intervention group
Group type: EXPERIMENTAL
Intervention: 6% dextran added to lignocaine solution containing adrenaline
Number of subjects: 27
Study 2454128 — intervention group
Group type: COMPARATOR
Intervention: Lignocaine solution containing adrenaline without dextran
Number of subjects: 27
Study 30764649 — intervention group
Group type: EXPERIMENTAL
Intervention: Conventional 10-Hz rTMS
Number of subjects: 388
Study 30764649 — intervention group
Group type: COMPARATOR
Intervention: Intermittent theta burst stimulation (iTBS) rTMS
Number of subjects: 388
Study 29074098 — intervention group
Group type: EXPERIMENTAL
Intervention: Lorlatinib (100 mg once daily)
Number of subjects: 54
Study 25212278 — intervention group
Group type: EXPERIMENTAL
Intervention: IMN (0.6 L/d)
Number of subjects: 120
Study 25212278 — intervention group
Group type: COMPARATOR
Intervention: CON (isocaloric control)
Number of subjects: 120
Study 25212278 — intervention group
Group type: EXPERIMENTAL
Intervention: IMN
Number of subjects: 120
Study 25212278 — intervention group
Group type: COMPARATOR
Intervention: CON
Number of subjects: 120
Study 24284608 — intervention group
Group type: EXPERIMENTAL
Intervention: Complementary foods from 4 months (CF)
Number of subjects: 119
Study 24284608 — intervention group
Group type: COMPARATOR
Intervention: Exclusive breastfeeding to 6 months (EBF)
Number of subjects: 119
Study 24284608 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups evaluated with Brigance Screens‐II at 30‐35 months
Number of subjects: 119
Study 22120443 — intervention group
Group type: EXPERIMENTAL
Intervention: Virtual Reality Exposure Therapy (VRE)
Number of subjects: 0
Study 22120443 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive Therapy (CT)
Number of subjects: 0
Study 22120443 — intervention group
Group type: COMPARATOR
Intervention: Cognitive-Behavior Therapy (CBT)
Number of subjects: 0
Study 22120443 — intervention group
Group type: COMPARATOR
Intervention: Wait List Controls (WL)
Number of subjects: 0
Study 19367116 — intervention group
Group type: EXPERIMENTAL
Intervention: Probiotics (various strains such as Bifidobacterium, Lactobacillus, and Lactococcus) administered during the perinatal period
Number of subjects: 0
Study 19367116 — intervention group
Group type: COMPARATOR
Intervention: Placebo (control group)
Number of subjects: 0
Study 16429250 — intervention group
Group type: EXPERIMENTAL
Intervention: SMART debriefing
Number of subjects: 51
Study 15110921 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydrocortisone (5 or 10 mg, p.o.)
Number of subjects: 16
Study 15110921 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study 15110921 — intervention group
Group type: EXPERIMENTAL
Intervention: CRH stimulation (1 g/kg i.v.)
Number of subjects: 16
Study 11128916 — intervention group
Group type: EXPERIMENTAL
Intervention: Coronally advanced flap (CAF) with enamel matrix derivative (EMD)
Number of subjects: 12
Study 11128916 — intervention group
Group type: COMPARATOR
Intervention: Coronally advanced flap (CAF) without enamel matrix derivative (EMD)
Number of subjects: 12
Study 9282767 — intervention group
Group type: EXPERIMENTAL
Intervention: Veress needle technique in the umbilicus
Number of subjects: 75
Study 9282767 — intervention group
Group type: EXPERIMENTAL
Intervention: Upper left quadrant insertion
Number of subjects: 75
Study 9282767 — intervention group
Group type: COMPARATOR
Intervention: Direct insertion with a disposable trocar in the umbilicus without pneumoperitoneum
Number of subjects: 75
Study 8463575 — intervention group
Group type: EXPERIMENTAL
Intervention: Mifepristone (200 mg on days 1 and 2)
Number of subjects: 120
Study 8463575 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 120
Study 8463575 — intervention group
Group type: EXPERIMENTAL
Intervention: Mifepristone
Number of subjects: 120
Study 2939218 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketanserin (K), 40 mg/day
Number of subjects: 24
Study 2939218 — intervention group
Group type: COMPARATOR
Intervention: Metoprolol (M), 200 mg/day
Number of subjects: 24
Study 2939218 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketanserin (K)
Number of subjects: 24
Study 2939218 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketanserin (K) plus Metoprolol (M)
Number of subjects: 24
Study 31895236 — intervention group
Group type: EXPERIMENTAL
Intervention: Arthroscopic Bankart repair (ABR)
Number of subjects: 88
Study 31895236 — intervention group
Group type: COMPARATOR
Intervention: Arthroscopic washout (AWO)
Number of subjects: 88
Study 29447347 — intervention group
Group type: EXPERIMENTAL
Intervention: 6-month lifestyle intervention
Number of subjects: 184
Study 29447347 — intervention group
Group type: COMPARATOR
Intervention: Comparison group
Number of subjects: 184
Study 27966652 — intervention group
Group type: EXPERIMENTAL
Intervention: Transcatheter PFO closure
Number of subjects: 258
Study 27966652 — intervention group
Group type: COMPARATOR
Intervention: Control group (no PFO closure)
Number of subjects: 258
Study 23588488 — intervention group
Group type: EXPERIMENTAL
Intervention: Foam rolling
Number of subjects: 26
Study 23588488 — intervention group
Group type: COMPARATOR
Intervention: Planking
Number of subjects: 26
Study 23588488 — intervention group
Group type: EXPERIMENTAL
Intervention: Foam rolling and Planking
Number of subjects: 26
Study 22246011 — intervention group
Group type: EXPERIMENTAL
Intervention: Carotid angioplasty stent placement (CAS)
Number of subjects: 182
Study 22246011 — intervention group
Group type: COMPARATOR
Intervention: Selective serotonin reuptake inhibitors (SSRIs)
Number of subjects: 182
Study 20002596 — intervention group
Group type: EXPERIMENTAL
Intervention: Milnacipran 200 mg/day
Number of subjects: 449
Study 20002596 — intervention group
Group type: EXPERIMENTAL
Intervention: Milnacipran 100 mg/day (re-randomized from placebo or milnacipran 100 mg/day)
Number of subjects: 449
Study 20002596 — intervention group
Group type: EXPERIMENTAL
Intervention: Milnacipran 200 mg/day (for patients re-randomized from placebo)
Number of subjects: 449
Study 20002596 — intervention group
Group type: COMPARATOR
Intervention: Placebo (initial treatment)
Number of subjects: 449
Study 18754195 — intervention group
Group type: EXPERIMENTAL
Intervention: Ibuprofen-releasing foam dressing (Biatain Ibu, ColoplastA/S)
Number of subjects: 853
Study 18754195 — intervention group
Group type: COMPARATOR
Intervention: Local best practice
Number of subjects: 853
Study 18754195 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 853
Study 15286005 — intervention group
Group type: EXPERIMENTAL
Intervention: Infliximab (3 mg/kg or 10 mg/kg every four or eight weeks)
Number of subjects: 428
Study 15286005 — intervention group
Group type: COMPARATOR
Intervention: Methotrexate alone
Number of subjects: 428
Study 12799626 — intervention group
Group type: EXPERIMENTAL
Intervention: Darbepoetin alpha QW (0.5, 1.0, 2.25, or 4.5 micro g kg(‐1) week(‐1) for 12 weeks)
Number of subjects: 188
Study 12799626 — intervention group
Group type: COMPARATOR
Intervention: Darbepoetin alpha Q3W (6.75 micro g kg(‐1) for 12 weeks)
Number of subjects: 188
Study 12799626 — intervention group
Group type: COMPARATOR
Intervention: Darbepoetin alpha Q4W (6.75 or 10.0 micro g kg(‐1) for 12 weeks)
Number of subjects: 188
Study 11382272 — intervention group
Group type: EXPERIMENTAL
Intervention: Audiovisual distraction
Number of subjects: 50
Study 11382272 — intervention group
Group type: COMPARATOR
Intervention: No-treatment control
Number of subjects: 50
Study 9780257 — intervention group
Group type: EXPERIMENTAL
Intervention: Ciprofloxacin 500 mg orally twice daily for 7 days
Number of subjects: 24
Study 9780257 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study 8195451 — intervention group
Group type: EXPERIMENTAL
Intervention: Clonazepam (mean dose 2.2 mg, SD 0.7 mg)
Number of subjects: 32
Study 8195451 — intervention group
Group type: EXPERIMENTAL
Intervention: Clonazepam
Number of subjects: 32
Study 8195451 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 32
Study 3658286 — intervention group
Group type: EXPERIMENTAL
Intervention: Doxycycline 400 mg
Number of subjects: 800
Study 3658286 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 800
Study 30700591 — intervention group
Group type: EXPERIMENTAL
Intervention: Aerobic exercise
Number of subjects: 132
Study 30700591 — intervention group
Group type: COMPARATOR
Intervention: Stretching/toning
Number of subjects: 132
Study 28328526 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin D3 (100,000 IU single oral dose)
Number of subjects: 107
Study 28328526 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 107
Study 26401670 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient mouth mask worn by the patient
Number of subjects: 60
Study 26401670 — intervention group
Group type: COMPARATOR
Intervention: No patient mouth mask worn
Number of subjects: 60
Study 24034569 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose Asiatic plantain extract (20 g/80 mL)
Number of subjects: 40
Study 24034569 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study 21964893 — intervention group
Group type: EXPERIMENTAL
Intervention: Bevacizumab containing chemotherapy
Number of subjects: 0
Study 19759073 — intervention group
Group type: EXPERIMENTAL
Intervention: Parents Plus Children's Programme (PPCP)
Number of subjects: 74
Study 19759073 — intervention group
Group type: COMPARATOR
Intervention: Treatment as Usual (TAU)
Number of subjects: 74
Study 17052276 — intervention group
Group type: EXPERIMENTAL
Intervention: PEG‐IFN (180 microg sc weekly) and standard dose of RBV (1000/1200 mg po daily, STD)
Number of subjects: 124
Study 17052276 — intervention group
Group type: COMPARATOR
Intervention: PEG‐IFN (180 microg sc weekly) and low‐dose of RBV (600/800 mg po daily, LOW)
Number of subjects: 124
Study 17052276 — intervention group
Group type: EXPERIMENTAL
Intervention: PEG‐IFN/STD RBV
Number of subjects: 124
Study 17052276 — intervention group
Group type: COMPARATOR
Intervention: PEG‐IFN/LOW RBV
Number of subjects: 124
Study 12588538 — intervention group
Group type: EXPERIMENTAL
Intervention: Investigational anticancer drugs
Number of subjects: 28
Study 12588538 — intervention group
Group type: COMPARATOR
Intervention: Earlier phases of investigational anticancer drugs
Number of subjects: 28
Study 10960412 — intervention group
Group type: EXPERIMENTAL
Intervention: Hyperbaric air (Group A)
Number of subjects: 36
Study 10960412 — intervention group
Group type: COMPARATOR
Intervention: Hyperbaric oxygen (Group O)
Number of subjects: 36
Study 9249272 — intervention group
Group type: EXPERIMENTAL
Intervention: Capsaicin
Number of subjects: 25
Study 9249272 — intervention group
Group type: COMPARATOR
Intervention: Placebo (NaCl 0.9%)
Number of subjects: 25
Study 8445198 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose methylprednisolone given within 8 hours of spinal cord injury
Number of subjects: 0
Study 8445198 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 30968729 — intervention group
Group type: EXPERIMENTAL
Intervention: Nivolumab (PD-1 blockade)
Number of subjects: 0
Study 30968729 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study 27209422 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive-behavioral treatment (CBT) in the form of exposure and response prevention, 14 weekly sessions
Number of subjects: 241
Study 26159101 — intervention group
Group type: EXPERIMENTAL
Intervention: Acetazolamide plus supervised diet
Number of subjects: 165
Study 26159101 — intervention group
Group type: COMPARATOR
Intervention: Placebo plus supervised diet
Number of subjects: 165
Study 24660585 — intervention group
Group type: EXPERIMENTAL
Intervention: Yishenjiangzhuo granules (YJG)
Number of subjects: 53
Study 24660585 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 53
Study 21677432 — intervention group
Group type: EXPERIMENTAL
Intervention: Cilostazol
Number of subjects: 100
Study 21677432 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 100
Study 18714248 — intervention group
Group type: EXPERIMENTAL
Intervention: Static stretching
Number of subjects: 24
Study 18714248 — intervention group
Group type: EXPERIMENTAL
Intervention: Ballistic stretching
Number of subjects: 24
Study 18714248 — intervention group
Group type: COMPARATOR
Intervention: No-stretch control condition
Number of subjects: 24
Study 18714248 — intervention group
Group type: EXPERIMENTAL
Intervention: All stretching conditions (static and ballistic)
Number of subjects: 24
Study 16520033 — intervention group
Group type: EXPERIMENTAL
Intervention: 60 mg/m2 every 6 weeks (ARM A)
Number of subjects: 116
Study 16520033 — intervention group
Group type: EXPERIMENTAL
Intervention: 50 mg/m2 every 4 weeks (ARM B)
Number of subjects: 116
Study 14739717 — intervention group
Group type: EXPERIMENTAL
Intervention: Dofetilide
Number of subjects: 506
Study 14739717 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 506
Study 10714017 — intervention group
Group type: EXPERIMENTAL
Intervention: Nicorandil pretreatment (0.3 mg/kg) 30 minutes before aortic cross clamping
Number of subjects: 40
Study 10714017 — intervention group
Group type: COMPARATOR
Intervention: Control group (not pretreated with nicorandil)
Number of subjects: 40
Study 8959996 — intervention group
Group type: EXPERIMENTAL
Intervention: 50 mg riluzole
Number of subjects: 959
Study 8959996 — intervention group
Group type: EXPERIMENTAL
Intervention: 100 mg riluzole
Number of subjects: 959
Study 8959996 — intervention group
Group type: EXPERIMENTAL
Intervention: 200 mg riluzole
Number of subjects: 959
Study 8959996 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 959
Study 8959996 — intervention group
Group type: EXPERIMENTAL
Intervention: Riluzole (any dose)
Number of subjects: 959
Study 1552399 — intervention group
Group type: EXPERIMENTAL
Intervention: Partial plasma exchange transfusion (PPET)
Number of subjects: 71
Study 1552399 — intervention group
Group type: COMPARATOR
Intervention: Observation
Number of subjects: 71
Study 1552399 — intervention group
Group type: COMPARATOR
Intervention: Control group (normal viscosity)
Number of subjects: 71
Study 1552399 — intervention group
Group type: EXPERIMENTAL
Intervention: Symptomatic hyperviscosity
Number of subjects: 71
Study 1552399 — intervention group
Group type: EXPERIMENTAL
Intervention: Asymptomatic hyperviscosity
Number of subjects: 71
Study 1552399 — intervention group
Group type: EXPERIMENTAL
Intervention: PPET
Number of subjects: 71
Study 4088224 — intervention group
Group type: EXPERIMENTAL
Intervention: Splenectomy (+)
Number of subjects: 0
Study 4088224 — intervention group
Group type: COMPARATOR
Intervention: Splenectomy (−)
Number of subjects: 0
Study 29533998 — intervention group
Group type: EXPERIMENTAL
Intervention: Daily vitamin D therapy
Number of subjects: 151
Study 29533998 — intervention group
Group type: COMPARATOR
Intervention: Depot vitamin D therapy
Number of subjects: 151
Study 25782919 — intervention group
Group type: EXPERIMENTAL
Intervention: Ropivacaine (0.25%, 40 mL)
Number of subjects: 108
Study 25782919 — intervention group
Group type: COMPARATOR
Intervention: Control (0.9% saline, 40 mL)
Number of subjects: 108
Study 25782919 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 108
Study 24447501 — intervention group
Group type: EXPERIMENTAL
Intervention: Levosimendan (6 μg/kg loading dose followed by 0.1 μg/kg/min infusion for 24 hours)
Number of subjects: 128
Study 24447501 — intervention group
Group type: COMPARATOR
Intervention: Standard inotropic therapy
Number of subjects: 128
Study 24447501 — intervention group
Group type: EXPERIMENTAL
Intervention: Levosimendan
Number of subjects: 128
Study 23304974 — intervention group
Group type: EXPERIMENTAL
Intervention: Subgroup 1: diamond disk followed by a fine Sof-lex disc
Number of subjects: 60
Study 23304974 — intervention group
Group type: EXPERIMENTAL
Intervention: Subgroup 4: diamond disk and chemical stripping using 37% orthophosphoric acid in conjunction with a fine 3M finishing strip
Number of subjects: 60
Study 23304974 — intervention group
Group type: EXPERIMENTAL
Intervention: All proximal stripping and polishing methods
Number of subjects: 60
Study 23304974 — intervention group
Group type: COMPARATOR
Intervention: Subgroup 5 (control): no stripping nor polishing
Number of subjects: 60